The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

在传统的HIV预防方法中，使用抗病毒药物通常需要每日服用，这不仅增加了患者的用药负担，也降低了患者每日坚持服药的依从性。以lenacapavir为代表的长效疗法，将可能为用户提供更为便利的选择。这种疗法通过每年肌肉注射的方式来维持HIV的抑制效果。一 ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

The new study, published in The Lancet, found that a yearly injection lenacapavir, made by Gilead Sciences ... data show the potential for biomedical HIV prevention with a once-yearly dosing ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...